trabodenoson

Trabodenoson is a small molecule investigational drug developed for the treatment of primary open-angle glaucoma and ocular hypertension. It acts as a potent and highly selective adenosine A1 receptor agonist, with over 10,000-fold selectivity versus the adenosine A2 receptor. Trabodenoson lowers intraocular pressure (IOP) by increasing aqueous humor outflow through the trabecular meshwork, which is achieved by upregulating proteases such as matrix metalloproteinase (MMP-2) that help clear extracellular matrix proteins blocking fluid flow. This mechanism directly targets the conventional outflow pathway in the eye—a novel approach compared to existing therapies that primarily affect other pathways or reduce fluid production. Clinical trials demonstrated dose-dependent IOP reduction with good tolerability; however, phase III development was discontinued after pivotal trials failed to meet endpoints, likely due to dosing regimen issues[1][2][3][4][5][6][8].

Other names

N-Cyclopentyladenosine 5'-nitrateN6-Cyclopentyladenosine 5'-nitrate